FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2982021808> ?p ?o ?g. }

• W2982021808 endingPage "141" @default.
• W2982021808 startingPage "129" @default.
• W2982021808 abstract "Linagliptin, a dipeptidyl peptidase-4 inhibitor, demonstrated cardiovascular and renal safety in type 2 diabetes mellitus (T2DM) patients with established cardiovascular disease (CVD) with albuminuria and/or kidney disease in the multinational CARMELINA® trial. We investigated the effects of linagliptin in Asian patients in CARMELINA®.T2DM patients with HbA1c 6.5-10.0% and established CVD with urinary albumin-to-creatinine ratio (UACR) > 30 mg/g, and/or prevalent kidney disease (estimated glomerular filtration rate [eGFR] 15-< 45 ml/min/1.73 m2 or ≥ 45-75 with UACR > 200 mg/g), were randomized to linagliptin or placebo added to usual care. The primary endpoint was time to first occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke (3-point MACE).Of the 6979 patients, 555 (8.0%) were Asians living in Asia. During a median follow-up of 2.2 years, 3-point MACE occurred in 29/272 (10.7%) and 33/283 (11.7%) of linagliptin and placebo patients, respectively (hazard ratio [HR] 0.90; 95% confidence interval [CI] 0.55-1.48), consistent with the overall population (HR 1.02; 95% CI 0.89-1.17; P value for treatment-by-region interaction: 0.3349). Similar neutrality in Asian patients was seen for other cardiorenal events including the secondary kidney endpoint of death from renal failure, progression to end-stage kidney disease, or ≥ 40% eGFR decrease (HR 0.96; 95% CI 0.58-1.59). Linagliptin was associated with a nominal decrease in the risk of hospitalization for heart failure (HR 0.47; 95% CI 0.24-0.95). Overall in Asian patients, linagliptin had an adverse event rate similar to placebo, consistent with the overall population.Linagliptin showed cardiovascular and renal safety in Asian patients with T2DM and established CVD with albuminuria and/or kidney disease." @default.
• W2982021808 created "2019-11-01" @default.
• W2982021808 creator A5008842761 @default.
• W2982021808 creator A5018481785 @default.
• W2982021808 creator A5027054516 @default.
• W2982021808 creator A5027520502 @default.
• W2982021808 creator A5033368647 @default.
• W2982021808 creator A5034066967 @default.
• W2982021808 creator A5036113498 @default.
• W2982021808 creator A5043895658 @default.
• W2982021808 creator A5045489578 @default.
• W2982021808 creator A5046517816 @default.
• W2982021808 creator A5048460362 @default.
• W2982021808 creator A5057781163 @default.
• W2982021808 creator A5067347864 @default.
• W2982021808 creator A5067356779 @default.
• W2982021808 creator A5067782612 @default.
• W2982021808 creator A5077189198 @default.
• W2982021808 creator A5083581289 @default.
• W2982021808 date "2019-10-22" @default.
• W2982021808 modified "2023-10-16" @default.
• W2982021808 title "Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial" @default.
• W2982021808 cites W1490158739 @default.
• W2982021808 cites W1496935057 @default.
• W2982021808 cites W1567871412 @default.
• W2982021808 cites W1771498646 @default.
• W2982021808 cites W1976612118 @default.
• W2982021808 cites W1998827401 @default.
• W2982021808 cites W2005041748 @default.
• W2982021808 cites W2028518937 @default.
• W2982021808 cites W2052330038 @default.
• W2982021808 cites W2056526409 @default.
• W2982021808 cites W2064130493 @default.
• W2982021808 cites W2068691394 @default.
• W2982021808 cites W2069585088 @default.
• W2982021808 cites W2090078712 @default.
• W2982021808 cites W2109911153 @default.
• W2982021808 cites W2127854619 @default.
• W2982021808 cites W2142830692 @default.
• W2982021808 cites W2146898936 @default.
• W2982021808 cites W2155104557 @default.
• W2982021808 cites W2179933935 @default.
• W2982021808 cites W2256422497 @default.
• W2982021808 cites W2279419135 @default.
• W2982021808 cites W2343414751 @default.
• W2982021808 cites W2486646922 @default.
• W2982021808 cites W2530634871 @default.
• W2982021808 cites W2534221266 @default.
• W2982021808 cites W2567447584 @default.
• W2982021808 cites W2639738157 @default.
• W2982021808 cites W2749709425 @default.
• W2982021808 cites W2754770935 @default.
• W2982021808 cites W2756246648 @default.
• W2982021808 cites W2788483598 @default.
• W2982021808 cites W2794676804 @default.
• W2982021808 cites W2804712568 @default.
• W2982021808 cites W2894993577 @default.
• W2982021808 cites W2900102850 @default.
• W2982021808 cites W2900149048 @default.
• W2982021808 cites W2908299731 @default.
• W2982021808 cites W4211190017 @default.
• W2982021808 cites W4212810717 @default.
• W2982021808 doi "https://doi.org/10.1007/s13340-019-00412-x" @default.
• W2982021808 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7082467" @default.
• W2982021808 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32206483" @default.
• W2982021808 hasPublicationYear "2019" @default.
• W2982021808 type Work @default.
• W2982021808 sameAs 2982021808 @default.
• W2982021808 citedByCount "17" @default.
• W2982021808 countsByYear W29820218082020 @default.
• W2982021808 countsByYear W29820218082021 @default.
• W2982021808 countsByYear W29820218082022 @default.
• W2982021808 crossrefType "journal-article" @default.
• W2982021808 hasAuthorship W2982021808A5008842761 @default.
• W2982021808 hasAuthorship W2982021808A5018481785 @default.
• W2982021808 hasAuthorship W2982021808A5027054516 @default.
• W2982021808 hasAuthorship W2982021808A5027520502 @default.
• W2982021808 hasAuthorship W2982021808A5033368647 @default.
• W2982021808 hasAuthorship W2982021808A5034066967 @default.
• W2982021808 hasAuthorship W2982021808A5036113498 @default.
• W2982021808 hasAuthorship W2982021808A5043895658 @default.
• W2982021808 hasAuthorship W2982021808A5045489578 @default.
• W2982021808 hasAuthorship W2982021808A5046517816 @default.
• W2982021808 hasAuthorship W2982021808A5048460362 @default.
• W2982021808 hasAuthorship W2982021808A5057781163 @default.
• W2982021808 hasAuthorship W2982021808A5067347864 @default.
• W2982021808 hasAuthorship W2982021808A5067356779 @default.
• W2982021808 hasAuthorship W2982021808A5067782612 @default.
• W2982021808 hasAuthorship W2982021808A5077189198 @default.
• W2982021808 hasAuthorship W2982021808A5083581289 @default.
• W2982021808 hasBestOaLocation W29820218082 @default.
• W2982021808 hasConcept C126322002 @default.
• W2982021808 hasConcept C134018914 @default.
• W2982021808 hasConcept C142724271 @default.
• W2982021808 hasConcept C159641895 @default.
• W2982021808 hasConcept C168563851 @default.
• W2982021808 hasConcept C203092338 @default.
• W2982021808 hasConcept C204787440 @default.

• next